A
Andy I. Chen
Researcher at Oregon Health & Science University
Publications - 90
Citations - 3037
Andy I. Chen is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 23, co-authored 73 publications receiving 2437 citations. Previous affiliations of Andy I. Chen include Stanford University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz,Auayporn Nademanee,Tamas Masszi,Edward Agura,Jerzy Holowiecki,Muneer H. Abidi,Andy I. Chen,Patrick J. Stiff,Alessandro M. Gianni,Angelo Michele Carella,Dzhelil Osmanov,Veronika Bachanova,John W. Sweetenham,Anna Sureda,Dirk Huebner,Eric L. Sievers,Andy Chi,Emily K. Larsen,Naomi N. H. Hunder,Jan Walewski +19 more
TL;DR: Early consolidation with brentuximab vedotin after autologous stem-cell transplantation improved progression-free survival in patients with Hodgkin's lymphoma with risk factors for relapse or progression after transplantation.
Journal ArticleDOI
Ox40-Ligand Has a Critical Costimulatory Role in Dendritic Cell:T Cell Interactions
Andy I. Chen,Alexander J. McAdam,Janet E. Buhlmann,Sumi Scott,Mark L Lupher,Edward A. Greenfield,Peter Robert Baum,William Christian Fanslow,David M. Calderhead,Gordon J. Freeman,Arlene H. Sharpe +10 more
TL;DR: Ox40L has a critical costimulatory function in vitro and in vivo for dendritic cell:T cell interactions and is implicated in T cell homing and B cell activation.
Journal ArticleDOI
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser,Ian W. Flinn,Ranjana H. Advani,Laurie H. Sehn,Catherine Diefenbach,Kathryn S. Kolibaba,Oliver W. Press,Gilles Salles,Hervé Tilly,Andy I. Chen,Sarit Assouline,Bruce D. Cheson,Martin Dreyling,Anton Hagenbeek,Pier Luigi Zinzani,Surai Jones,Ji Cheng,Dan Lu,Elicia Penuel,Jamie Hirata,Michael Wenger,Yu Waye Chu,Jeff P. Sharman +22 more
TL;DR: R-pina and R-pola are potential treatment options in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, partly because of longer durations of response than pina, and an overall benefit-risk favouring R- pola.
Journal ArticleDOI
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz,Jan Walewski,Auayporn Nademanee,Tamás Masszi,Edward Agura,Jerzy Holowiecki,Muneer H. Abidi,Andy I. Chen,Patrick J. Stiff,Simonetta Viviani,Veronika Bachanova,Anna Sureda,Teresa McClendon,Connie Lee,Julie Lisano,John W. Sweetenham +15 more
TL;DR: Consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated.
Journal ArticleDOI
Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients
Bruce R. Blazar,Arlene H. Sharpe,Andy I. Chen,Angela Panoskaltsis-Mortari,Christopher J. Lees,Hisaya Akiba,Hideo Yagita,Nigel Killeen,Patricia A. Taylor +8 more
TL;DR: In vivo blockade of OX40-OX40L interactions reduced GVHD mortality induced by either signal transducer and activator of transcription-6 (-/-) (Stat-6(-/-)) (Th2-defective) or Stat-4-4(+/+) (Th1- defective) major histocompatibility complex (MHC)-disparate splenocytes, indicating that the GV HD-ameliorating effects did not require Stat- 4